IFNA1 and hepatocellular carcinoma: Recent studies have revealed that amino acid substitutions in the core region of different HCV genotypes are associated with IR[12], increased HCC risk[13-17], variable responses to double (IFN/RBV)[18-24] and triple (telaprevir plus INF/RBV) therapy[25,26], and liver steatosis[27-30].